Lynn Anne Bristol

Array ( [id] => 13428095 [patent_doc_number] => 20180265590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY [patent_app_type] => utility [patent_app_number] => 15/982141 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386473 [patent_doc_number] => 20180244778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => Humanized Antibodies to Cluster of Differentiation 3 (CD3) [patent_app_type] => utility [patent_app_number] => 15/979197 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622189 [patent_doc_number] => 20180362646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ANTI-CD33 ANTIBODIES AND METHOD FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME [patent_app_type] => utility [patent_app_number] => 15/978846 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15978846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16215156 [patent_doc_number] => 10730954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => MSLN targeting trispecific proteins and methods of use [patent_app_type] => utility [patent_app_number] => 15/977988 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25630 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536689 [patent_doc_number] => 20180319888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION [patent_app_type] => utility [patent_app_number] => 15/977725 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268857 [patent_doc_number] => 20200270344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/610429 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -84 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391443 [patent_doc_number] => 20230159661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS [patent_app_type] => utility [patent_app_number] => 16/607783 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522089 [patent_doc_number] => 20180312587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => ANTI-SIRP ALPHA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/953201 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15953201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793407 [patent_doc_number] => 20190010242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 15/951137 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15951137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312392 [patent_doc_number] => 20200291130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => ANTIBODIES FOR THE TREATMENT OF ERBB-2/ERBB-3 POSITIVE TUMORS [patent_app_type] => utility [patent_app_number] => 16/499723 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19075300 [patent_doc_number] => 11944643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Universal anti-CD22 chimeric antigen receptor engineered immune cells [patent_app_type] => utility [patent_app_number] => 16/498899 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 44112 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17392506 [patent_doc_number] => 11241494 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Method for eliciting an immune response to an immunogen [patent_app_type] => utility [patent_app_number] => 15/939232 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 5965 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15939232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134784 [patent_doc_number] => 11560437 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Stable multispecific antibodies [patent_app_type] => utility [patent_app_number] => 16/498421 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 15 [patent_no_of_words] => 12569 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12885133 [patent_doc_number] => 20180186886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => Anti-Neuropilin Antigen-Binding Proteins and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 15/900158 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681327 [patent_doc_number] => 20200095327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => ANTIBODY HEAVY CHAIN VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/483572 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102426 [patent_doc_number] => 11542301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Fc-binding protein having improved antibody separation ability, and method for separating antibody using same [patent_app_type] => utility [patent_app_number] => 16/486380 [patent_app_country] => US [patent_app_date] => 2018-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 12544 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391059 [patent_doc_number] => 20200332000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => LOW PH PHARMACEUTICAL COMPOSITION COMPRISING T CELL ENGAGING ANTIBODY CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/482603 [patent_app_country] => US [patent_app_date] => 2018-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16482603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12770035 [patent_doc_number] => 20180148513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => ANTI-PD-1 ANTIBODIES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 15/875970 [patent_app_country] => US [patent_app_date] => 2018-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15875970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460798 [patent_doc_number] => 10844133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Cancer therapy using CLDN6 target-directed antibodies in vivo [patent_app_type] => utility [patent_app_number] => 15/866139 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 24825 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038745 [patent_doc_number] => 20190330377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => A POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/476624 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476624 [rel_patent_id] =>[rel_patent_doc_number] =>)